# US 2014/0193418 A1 · Anti-human epo receptor antibodies and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193418 A1
- Document ID: US20140193418A1
- Status: Published application
- Kind: A1
- Application number: 14/097,972
- Filed: 2013-12-05
- Published: 2014-07-10
- Earliest claimed: 2011-06-15
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Michael Jarsch; Olaf Mundigl
- Web page: https://patentgrep.com/patent/US20140193418A1

## CPC

- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- G01N 33/56966: {Animal cells}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.

## Claims

### Claim 1

A method for detecting in vitro human EPO receptor comprising the following step
determining in vitro the presence of human EPO receptor in a sample by incubating the sample with an EPO receptor antibody that specifically binds to human EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) and thereby detecting in vitro human EPO receptor,
wherein the EPO receptor antibody that specifically binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.

### Claim 2

An antibody that specifically binds to human EPO receptor, characterized in that the antibody binds to human EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) and does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 2)

A method for predicting or determining the responsiveness of a patient towards a medicament for increasing the number of red blood cells comprising
determining in vitro the presence of the human EPO receptor on cancer cells of the patient, by incubating in vitro a sample of the patient with the EPO receptor antibody of claim 2 and determining in vitro the binding of the antibody of claim 2 to the sample, and
associating the presence of the human EPO receptor on the cancer cells of the patient with the responsiveness of the patient towards a medicament for increasing the number of red blood cells.

### Claim 7

A method for producing an antibody that specifically binds to human EPO receptor comprising the following steps:
immunizing an animal with a polypeptide comprising the EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO: 02), and
selecting an antibody specifically binding to the EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) and thereby producing an antibody that specifically binds to human EPO receptor.

### Claim 8 (depends on 2)

The antibody according to claim 2, wherein the antibody does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 58 kD to about 70 kD.

### Claim 9 (depends on 2)

The antibody according to claim 2, wherein the antibody binds to a protein obtainable from human endothelial cells with an affinity of 10−3M or higher.

### Claim 10 (depends on 2)

The antibody according to claim 2, wherein the antibody is a polyclonal antibody or a monoclonal antibody.

### Claim 11 (depends on 2)

The antibody according to claim 2, wherein the antibody is a human, humanized, or chimeric antibody.

### Claim 12 (depends on 2)

The antibody according to claim 2, wherein the antibody is an antibody fragment that binds human EPO receptor.

### Claim 13 (depends on 2)

A pharmaceutical formulation comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 2)

An isolated nucleic acid encoding the antibody according to claim 2.

### Claim 15 (depends on 14)

A host cell comprising the nucleic acid of claim 14.

### Claim 16 (depends on 2)

A diagnostic kit comprising an antibody according to claim 2.

### Claim 17 (depends on 2)

A method for analysis of EPO receptor in a human tissue or cell sample using an antibody of claim 2.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the sample is a lysate of human tissue or cells, or a section of human tissue, or a section of a fresh human tissue, or frozen human tissue, or a section of frozen human tissue, or formalin-fixed paraffin embedded human tissue, or a section of formalin-fixed paraffin embedded human tissue.

### Claim 19 (depends on 17)

The method according to claim 17, wherein analysis is performed by immunochemistry, immunofluorescence or immunohistochemistry.

### Claim 20 (depends on 17)

The method according to claim 17, wherein analysis is performed by Western Blot.